Bai Yifei, Geng Xu, Jia Zhongzhi, Xue Tongqing, Wang Kai
Department of Interventional and Vascular Surgery, The Third Affiliated Hospital of Nanjing Medical University (Changzhou Second People's Hospital), Changzhou, China.
Department of Interventional Radiology, Huaian Hospital of Huai'an City (Huaian Cancer Hospital), Huai'an, China.
J Vasc Surg Venous Lymphat Disord. 2025 May 10;13(5):102259. doi: 10.1016/j.jvsv.2025.102259.
The goal of this study was to evaluate the incidence, predictors, and clinical outcomes of thrombus propagation in patients with isolated calf muscle venous thrombosis (CMVT).
This retrospective observational study included all consecutive hospitalized patients who were diagnosed with isolated CMVT between January 1, 2022, and August 1, 2024. Data on demographics, comorbidities, laboratory biomarkers, and management strategies were collected. The primary end point was the incidence of thrombus propagation (defined as either a previously localized thrombi within the muscular calf veins that was found to extend to the axis calf veins or proximal veins of the ipsilateral extremity or as a thrombus that had clearly extended but remained confined to the muscular calf veins) during follow-up. Secondary end points included the incidence of venous thromboembolism (VTE) recurrence (defined as the formation of a new thrombus [ipsilateral or contralateral deep vein thrombosis or pulmonary embolism] confirmed by imaging during follow-up after complete resolution of the original CMVT), bleeding events, rehospitalization, and death.
Among the 459 patients included in this study, the incidence of CMVT propagation was 8.7% (n = 40). Independent predictors of thrombus propagation were immobilization (odds ratio [OR]; 3.06 [95% confidence interval, 1.04-8.99]; P = .042), history of VTE (OR, 4.31 [95% CI, 1.42-13.05]; P = .010), and elevated D-dimer level (OR, 1.06 [95% CI, 1.02-1.09]; P = .003). The mean time to propagation was 9.3 ± 5.2 days. VTE recurrence rates were 2.5% (n = 1) in patients with propagation and 1.7% (n = 7) in patients without propagation (P = .702). Major bleeding events occurred in 5.0% of patients (n = 2) with propagation and in 3.1% of patients (n = 13) without propagation (P = .519). During the follow-up period, no patients were rehospitalized or died owing to VTE events.
Thrombus propagation in patients with isolated CMVT is uncommon and generally not fatal. Predictors of CMVT propagation include immobilization, history of VTE, and elevated D-dimer level. These findings may help to identify patients with a significant risk of CMVT propagation.
本研究的目的是评估单纯小腿肌肉静脉血栓形成(CMVT)患者血栓扩展的发生率、预测因素和临床结局。
这项回顾性观察性研究纳入了2022年1月1日至2024年8月1日期间所有连续住院的被诊断为单纯CMVT的患者。收集了人口统计学、合并症、实验室生物标志物和管理策略的数据。主要终点是随访期间血栓扩展的发生率(定义为小腿肌肉静脉内先前局限的血栓扩展至小腿轴静脉或同侧肢体的近端静脉,或血栓明显扩展但仍局限于小腿肌肉静脉)。次要终点包括静脉血栓栓塞(VTE)复发率(定义为在原CMVT完全消退后的随访期间通过影像学确认形成新的血栓[同侧或对侧深静脉血栓形成或肺栓塞])、出血事件、再次住院和死亡。
在本研究纳入的459例患者中,CMVT扩展的发生率为8.7%(n = 40)。血栓扩展的独立预测因素为制动(比值比[OR];3.06[95%置信区间,1.04 - 8.99];P = .042)、VTE病史(OR,4.31[95%CI,1.42 - 13.05];P = .010)和D - 二聚体水平升高(OR,1.06[95%CI,1.02 - 1.09];P = .003)。扩展的平均时间为9.3±5.2天。扩展患者的VTE复发率为2.5%(n = 1),未扩展患者为1.7%(n = 7)(P = .702)。扩展患者中有5.0%(n = 2)发生大出血事件,未扩展患者中有3.1%(n = 13)发生大出血事件(P = .519)。在随访期间,没有患者因VTE事件再次住院或死亡。
单纯CMVT患者的血栓扩展并不常见,通常不会致命。CMVT扩展的预测因素包括制动、VTE病史和D - 二聚体水平升高。这些发现可能有助于识别CMVT扩展风险较高的患者。